Search
Following the emphasis on cybersecurity, the biological domain has emerged as a fresh focal point for safety within the AI industry. Prominent companies like Anthropic, OpenAI, and Google DeepMind are ramping up their investments in biological risk assessment and access control measures. Their goal is to prevent AI from being misused in the creation of novel viruses or biological weapons. Anthropic has refined the Claude Fable 5 model to minimize false interceptions. Meanwhile, OpenAI has initiated the GPT-Rosalind biodefense program, which provides funding for developers to create biodefense applications. Additionally, Google DeepMind has forged 15 collaborative partnerships with Isomorphic Labs to collectively tackle AI-related biological risks.
-
C114 Communication Network -
Communication Home
